Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$0 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-7 Mln
ROE
-1.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
EV/EBITDA
0.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
4,271,760
CFO
$-129.51 Mln
EBITDA
$-139.68 Mln
Net Profit
$-179.54 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Histogen (HSTO)
| -2.5 | -2.5 | -91.0 | -92.7 | -81.7 | -79.7 | -65.8 |
|
BSE Sensex*
| 4.4 | 2.7 | 8.5 | 10.1 | 14.6 | 21.7 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|
|
Histogen (HSTO)
| -62.7 | -56.5 | -81.1 | -76.9 | -62.4 | -12.3 |
|
S&P Small-Cap 600
| 13.9 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Histogen (HSTO)
|
0.0 | 0.1 | 0.0 | -12.4 | -65,168.4 | -147.7 | -- | 0.0 |
| 0.0 | 0.0 | 0.0 | -31.6 | -- | -- | -- | 2.3 | |
| 1.9 | 20.3 | 0.0 | -27.7 | -640,975.0 | -240.9 | -- | 1.3 | |
| 39.2 | 7,216.0 | 261.6 | -697.5 | -234.6 | -38.3 | -- | 3.5 |
Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product... candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California. Read more
President, CEO, CFO, COO, Chief Compliance Officer & Corporate Secretary
Ms. Susan A. Knudson
President, CEO, CFO, COO, Chief Compliance Officer & Corporate Secretary
Ms. Susan A. Knudson
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Histogen Inc (HSTO) stood at $ 7 Mln as on 30-Sep-23
The share price of Histogen Inc (HSTO) is $0.03 (NASDAQ) as of 28-Jan-2025 09:30 EDT. Histogen Inc (HSTO) has given a return of -81.66% in the last 3 years.
Histogen Inc (HSTO) has a market capitalisation of $ 0 Mln as on 28-Jan-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Histogen Inc (HSTO) is 0.02 times as on 28-Jan-2025, a 99% discount to its peers’ median range of 2.34 times.
Since, TTM earnings of Histogen Inc (HSTO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Histogen Inc (HSTO) and enter the required number of quantities and click on buy to purchase the shares of Histogen Inc (HSTO).
Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.
The CEO & director of Ms. Susan A. Knudson. is Histogen Inc (HSTO), and CFO & Sr. VP is Ms. Susan A. Knudson.
There is no promoter pledging in Histogen Inc (HSTO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
701
|
|
|
2
|
|
|
0
|
|
|
701
|
|
|
2
|
|
|
0
|
| Histogen Inc. (HSTO) | Ratios |
|---|---|
|
Return on equity(%)
|
-147.67
|
|
Operating margin(%)
|
-65168.42
|
|
Net Margin(%)
|
-65278.95
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Histogen Inc (HSTO) was $-7 Mln.
